< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

RAPS European Digital Technologies and Software conference

Oktober 2025

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October.

HGF Partner and Patent Attorney Janine Swarbrick and Patent Director Roxna Kapadia will be speaking on the plenary masterclass Developing a Killer Intellectual Property Strategy for your AI Innovation:

Not to be missed, a masterclass on patent strategy development in the software/AI space from two patent attorneys from HGF, a firm which is highly ranked among Europe’s top patent firms. Artificial intelligence (AI) is playing an increasingly significant role in the rapidly evolving fields of healthcare and medical technology. With this innovation comes a complex legal landscape, particularly in relation to patent protection for AI-focused inventions in the physics/software and life sciences sectors. Guidance on strategy development, pitfalls and detailed requirements will be provided covering both physics/software and life science aspects of innovations in this space.

Learning Objectives

  • Understand how IP rights can be obtained and used to protect AI innovations in healthcare and life sciences
  • Hear case studies where IP strategies have successfully supported business goals in healthcare companies, and where early IP advice would have been beneficial.
  • Explore best practice in-house for identifying, and retaining value from, AI innovations in your business.

Janine will also be speaking on the opening plenary session Regulatory Compliance in the Age of AI:

We all feel that AI is rapidly transforming the regulatory compliance landscape and the trend will only accelerate in the coming years. AI is already impacting compliance and has immense potential to fundamentally change the field as we know it. We all need to do something with this- but what? And how? Let’s hear from our panelists.

Click the button to find out more.

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen